The HRH1 Knockout CAL-27 Polyclonal Cells represent a CRISPR/Cas9-edited polyclonal cell population with targeted disruption of the HRH1 gene in the CAL-27 human oral squamous cell carcinoma cell line. This loss-of-function model is generated using CRISPR/Cas9-mediated gene editing to create a heterogeneous knockout population, enabling functional studies without monoclonal isolation. The polyclonal format preserves cellular diversity and provides a robust tool for investigating HRH1-dependent signaling in an epithelial tumor context.
CAL-27 cells are derived from a human tongue squamous cell carcinoma and exhibit adherent epithelial morphology. Widely employed as a model for oral cancer research, these cells retain key characteristics of tumorigenic epithelium, including invasive potential and responsiveness to microenvironmental stimuli. The cell line provides a physiologically relevant background for studying histamine receptor function in head and neck malignancies, where HRH1 signaling may influence tumor progression and the inflammatory milieu.
HRH1 encodes the histamine H1 receptor, a Gq/11-coupled GPCR that mediates diverse cellular responses to histamine. Ligand binding triggers activation of phospholipase C?? (PLC??), generating second messengers inositol 1,4,5-trisphosphate (IP3) and diacylglycerol (DAG), which mobilize intracellular Ca2? and activate protein kinase C (PKC). Subsequently, downstream phosphorylation cascades involving ERK1/2, p38 MAPK, and JNK are initiated, culminating in the activation of transcription factors NF-??B and AP-1 (c-Fos/c-Jun). This signaling axis promotes expression of pro-inflammatory cytokines such as IL-6 and IL-8. HRH1 expression is upregulated by IL-4 and IL-13 through STAT6 and NF-??B, and receptor desensitization involves ??-arrestin1/2 and GRK2/5, highlighting a complex regulatory network. The knockout abrogates histamine-induced Gaq/11?CPLC?¨CCa2? signaling, providing a clean background for dissecting these pathways.
In the context of oral squamous cell carcinoma, HRH1-mediated signaling has been implicated in tumor-associated inflammation, proliferation, and metastatic behavior. Histamine, often elevated in the tumor microenvironment, may drive pro-tumorigenic responses through HRH1 on cancer cells. By eliminating HRH1 function, this polyclonal knockout model allows researchers to directly examine the receptor??s role in processes such as cell growth, migration, and cytokine production within CAL-27 cells. It also facilitates the study of crosstalk between histamine signaling and other oncogenic pathways, including MAPK and NF-??B cascades, which are frequently dysregulated in oral cancers.
This product is ideally suited for a wide array of functional assays, including Western blotting and RT-qPCR for confirming HRH1 disruption, calcium flux measurements using Fluo-4, phospho-ERK and phospho-p38 ELISAs, MTT proliferation assays, scratch wound healing and Transwell migration/invasion studies, and cytokine quantification (IL-6, IL-8) by ELISA. Additionally, NF-??B luciferase reporter assays and flow cytometry for cell surface HRH1 can be employed. Typical applications include investigation of histamine signaling in oral squamous cell carcinoma, screening of HRH1 antagonists for therapeutic potential, and elucidation of GPCR-mediated networks in the tumor microenvironment. For more information or to place an order, please contact Ascent Research.
